CICD Cancer Breakthrough

Researchers are suggesting that this new breakthrough may provide a more effective treatment for cancer.

In triggering CICD as opposed to apoptosis, researchers found that CICD often lead to complete tumour regression. Unlike apoptosis, CICD works by alerting the immune cells through releasing inflammatory proteins once the cancer cells die. Once the immune cells have been alerted, they begin to attack the remaining cancer cells.

In comparison to current treatments such as chemotherapy, radiation and immunotherapy that rely on killing cancer cells through apoptosis, the success rate of CICD in completely eradicating cancer is more than the conventional apoptosis method.

In research to demonstrate the potential of using CICD, researchers used lab-grown colorectal cancer cells to show the advantages of killing cancers cells using CICD.

The project was funded by Cancer Research UK and was lead by Dr. Stephen Tait at the University of Glasgow. Speaking on the research, Dr. Tait said that the new method ‘often led to complete tumour regression’ and ‘may be a more effective way to treat cancer’. He added:

"In essence, this mechanism has the potential to dramatically improve the effectiveness of anti-cancer therapy and reduce unwanted toxicity.

"Taking into consideration our findings, we propose that engaging CICD as a means of anti-cancer therapy warrants further investigation."

Dr Justine Alford, Cancer Research UK's senior science information officer, said:

"Although many cancer treatments work by triggering apoptosis, that method sometimes fails to finish the job and instead may lead to the tumour becoming harder to treat. This new research suggests there could be a better way to kill cancer cells which, as an added bonus, also activates the immune system."

To see more research that is advancing the oncology industry, register for your free ticket to attend the European Oncology Convention at ExCeL, London on the 6th & 7th June 2018 here.

Additionally, if you are interested in exhibiting to thousands of hospitals actively looking to purchase groundbreaking new drugs in the oncology field, please contact Nick Woore, Event Director on:

Tel: 01179296097

Email: Nick.Woore@prysmgroup.co.uk